Nine Square Therapeutics Corp — Form D/A
Nine Square Therapeutics Corp of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2021-02-03. The offering totals $50.0M, of which $4.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-02-03
- Form: D/A
- Accession: 0001816518-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $4.2M
- Remaining: $45.8M
- Investors: 1
- Date of first sale: 2020-06-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-370079
Issuer
- Name: Nine Square Therapeutics Corp
- CIK: 0001816518
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 230 PARK AVENUE, SUITE 2800, NEW YORK, NY, 10169
- Phone: 781-367-5419
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Michael Ehlers | Director | Morristown, NJ |
| Seth Harrison | Director | Redwood City, CA |
| Matthew Jacobson | Director | South San Francisco, CA |
| Spiros Liras | Director | New York, NY |
| Spiros Liras | Executive Officer | New York, NY |
Other filings by this issuer (1)
More